3,7-dimethyl-octa-1,6-dien-1-yl acetate | 57576-59-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3,7-dimethyl-octa-1,6-dien-1-yl acetate
• 英文别名: (E)-3,7-dimethylocta-1,6-dien-1-yl acetate；(E)-3,7-dimethyl-1,6-octadienyl acetate；3,7-dimethyl-1,6-octadienyl acetate；(E)-3,7-Dimethylocta-1,6-dienylacetat；[(1E)-3,7-dimethylocta-1,6-dienyl] acetate
• CAS: 57576-59-7
• 化学式: C₁₂H₂₀O₂
• 分子量: 196.29
• InChiKey: UGXCOBMTQQHYSO-CMDGGOBGSA-N

物化性质

• 沸点：
  264.6±19.0 °C(Predicted)
• 密度：
  0.902±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,7-dimethyl-octa-1,6-dien-1-yl acetate 在 磷酸 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以6.5 g的产率得到2,2,6-三甲基环己烷甲醛
  参考文献：
  名称：

  Expansion of First-in-Class Drug Candidates That Sequester Toxic All-Trans-Retinal and Prevent Light-Induced Retinal Degeneration

  摘要：

  全反视黄醛是一种视黄酸代谢物，在光感受器光激活后自然产生，当其在视网膜中含量升高时具有细胞毒性。为了降低其毒性，人们已开发出两种实验验证的方法，包括抑制视黄酸循环和通过含有伯胺基团的药物捕获过量的全反视黄醛。我们鉴定了首批候选药物，这些药物通过暂时捕获该代谢物或通过抑制视觉色素11-顺式视黄醛的再生来减缓其产生。在眼睛中，有两种酶对视黄酸的循环至关重要。卵磷脂：视黄醇酰基转移酶（LRAT）是将从循环和光感受器细胞中捕获的维生素A（全反视黄醇）转化为酯化底物的酶，该底物供视黄酸异构酶（RPE65）使用，后者将全反视黄醇酯转化为11-顺式视黄醇。在此，我们研究了视黄胺及其衍生物，以评估它们对RPE65和LRAT的抑制剂/底物特异性、作用机制、效力、在眼睛中的保留能力以及对小鼠急性光诱导视网膜变性的保护作用。我们将视觉循环抑制水平与视网膜保护效应相关联，并概述了LRAT底物和RPE65抑制剂的化学边界，以获得对视网膜保持所需治疗特性的关键洞察。

  DOI：

  10.1124/mol.114.096560
• 作为产物：
  描述：

  7anti-acetoxy-(2exoH)-pinane 生成 3,7-dimethyl-octa-1,6-dien-1-yl acetate
  参考文献：
  名称：

  Cant,P.A.E. et al., Australian Journal of Chemistry, 1975, vol. 28, p. 391 - 397

  摘要：

  DOI：

文献信息

• [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS LIANT L'OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2013081642A1

  公开（公告）日：2013-06-06

  Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  揭示了用于治疗由于或与在眼睛中积聚的有毒视觉循环产物有关的眼科疾病的化合物和组合物，例如干性成人黄斑变性，以及由于或与突变视蛋白的错误折叠和/或视蛋白的错误定位有关的疾病。还描述了这些化合物单独或与其他治疗剂的组合物，以及使用这些化合物和/或组合物的治疗方法。还揭示了合成这些药剂的方法。
• [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS DE LIAISON AUX OPSINES, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2013082000A1

  公开（公告）日：2013-06-06

  Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  披露了一些化合物，这些化合物对治疗由于或与在眼睛中积累的有毒视觉循环产物有关的眼科疾病非常有用，例如干性成人黄斑变性，以及由于或与突变视蛋白的错误折叠和/或视蛋白的错误定位有关的疾病。还描述了这些化合物单独或与其他治疗剂联合使用的组合物，以及使用这些化合物和/或组合物的治疗方法。还披露了合成这些药剂的方法。
• [EN] OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] LIGANDS DE LIAISON À UNE OPSINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：BIKAM PHARMACEUTICALS INC

  公开号：WO2012174064A1

  公开（公告）日：2012-12-20

  Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

  披露了一些化合物，可用于治疗由或与在眼睛中积聚的有毒视觉循环产物有关的眼科疾病，例如干性成人黄斑变性，以及由或与突变视蛋白的错误折叠和/或视蛋白的错误定位有关的疾病。还描述了这些化合物单独或与其他治疗剂结合的组合物，以及使用这些化合物和/或组合物的治疗方法。还披露了合成这些药剂的方法。
• Aldehyde Enol Esters as Novel Chain Terminators in Cationic Olefin Cyclizations
  作者：Dana P. Simmons、Daniel Reichlin、David Skuy

  DOI：10.1002/hlca.19880710509

  日期：1988.8.10

  Citronella (1) has been transformed into enol acetates 2 which have been cyclized with various Lewis and Brönsted acids to dihydrocyclocitral (4). Application of this methodology to the synthesis of mono- and bicyclic ring systems has been examined.

  香茅油（1）已转化为烯醇乙酸酯2，已用各种路易斯酸和布朗斯台德酸环化成二氢环柠檬酸（4）。已经研究了该方法在单环和双环系统合成中的应用。
• METHOD FOR RELEASING UNSATURATED ALDEHYDE OR KETONE
  申请人：TAKASAGO INTERNATIONAL CORPORATION

  公开号：US20190185494A1

  公开（公告）日：2019-06-20

  The present invention relates to a method for releasing an unsaturated aldehyde or ketone represented by the general formula (2) by irradiating the compound represented by the general formula (1) with light, in which the compound represented by the general formula (1) is used as a flavor or fragrance precursor:

  本发明涉及一种通过用光辐射来释放由通用式（2）表示的不饱和醛或酮的方法，其中所述通用式（1）表示的化合物被用作风味或香料前体：